1.	Phase III Multicenter, Pivotal Study of Iodine 131 Anti-B1 Antibody Radioimmunotherapy for Chemotherapy-Refractory Low Grade B-Cell Non-Hodgkin's Lymphomas or Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (Summary Last Modified 10/98) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: COULTER-RIT-11-004, NCI-V97-1245
2.	S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068321, U10CA032102, S0016, CALGB-50102, SWOG-S0016, ECOG-SWOG-S0016, NCT00006721
3.	Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 80 Sponsor: NCI, NHLBI Protocol IDs: 384, BMT CTN 0401, U01 HL069294-05, FHCRC-2125.00, NCT00329030
4.	hase II Study of Combined B-Cell Purging and CD34+ Enrichment of Mobilized Peripheral Blood Progenitor Cells for Autologous Hematopoietic Transplantation in Patients with Relapsed Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 14 to 70 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CWRU-CELL-1497, CP-0154-010, NCI-G98-1430
5.	S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000066917, S9911, U10CA032102, SWOG-9911, NCT00003784
6.	Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 to 59 Sponsor: NCI, Other Protocol IDs: 1368.00, NCI-2009-01469, P01CA044991, FHCRC-1368.00, NCT00073918
7.	Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP Phase: Phase II Type: Treatment Status: Closed Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: CP-99-032, NCT00022932
8.	Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CP-99-037, NCT00022945
9.	Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000415955, SWOG-S0433, S0433, NCT00107380
10.	Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2005.035, IRB # 2005-0403 and HUM 43767, NCT00135200
11.	Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 393229/032, NCT00240565
12.	Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: PSOC 2301, NCI-2011-01311, NCT00476047
13.	A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: LYM 2005-01, NCT00479167
14.	Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 19 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LYMNHL0019, 10275, NCT00490009
15.	Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 19 and over Sponsor: Other Protocol IDs: LYMNHL0046, 97437, 7479, NCT00490490
16.	Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 60 to 80 Sponsor: NCI, Other Protocol IDs: 1366.00, CDR0000341125, FHCRC-1366.00, NCT00073931
17.	Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 19 to 70 Sponsor: Other Protocol IDs: 051-00, UNMC-051-00, COULTER-IND-3323, NCT00006695
18.	Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma Phase: Phase I Type: Treatment Status: Closed Age: 60 and over Sponsor: NCI, Other Protocol IDs: 1943.00, NCI-2009-01470, P01CA044991, FHCRC-1943.00, NCT00110071
19.	Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 100 Sponsor: NCI, Other Protocol IDs: JHOC-J0636, CDR0000522705, NCT00416312